Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice

(2010) C. Marty et al.   BLOOD

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

(2010) H. Akada et al.   BLOOD

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

(2010) J. Li et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt

(2010) Elena Mishchenko et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis

(2009) Danzhi Huang et al.   BIOINFORMATICS

Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera

(2009) M. L. Randi et al.   BLOOD

Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity

(2009) P. C.C. Liu et al.   CLINICAL CANCER RESEARCH

Blood cell activation in myeloproliferative neoplasms

(2009) F. Cervantes et al.   HAEMATOLOGICA

Identification of a novel TEL–Lyn fusion gene in primary myelofibrosis

(2009) H Tanaka et al.   LEUKEMIA

Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy

(2008) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

(2008) S. Xing et al.   BLOOD

Dasatinib inhibits progenitor cell proliferation from polycythaemia vera

(2008) M. Wappl et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD